TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

Tharimmune, Inc., (Nasdaq:THAR) (”Tharimmune” or the “Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology announced ...

Discover groundbreaking research and presentations from leading companies at the ARVO 2025 Annual Meeting, advancing ...

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and ...

FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced that a plixorafenib abstract has been ...

Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, today announced that Co-Founder ...

BRIDGEWATER, NJ / ACCESS Newswire / May 1, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeuti ...

The company’s exhibitions will be focused in the areas of its pipeline, proprietary capsid engineering, and manufacturing.

A copy of the presentation materials will be added to the " Publications ” section of the Company's website at tscan.com once the presentation has concluded. About TScan Therapeutics, Inc.

SEATTLE, April 28, 2025 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader in RNA-based gene therapy, today announced the acceptance of multiple abstracts, including two oral presentations ...